Research Topics
| D F RansohoffSummaryAffiliation: University of North Carolina Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cultivating cohort studies for observational translational researchDavid F Ransohoff
UNC CH, Chapel Hill, NC 27599, USA
Cancer Epidemiol Biomarkers Prev 22:481-4. 2013..What are the reasons, and can observational cohorts be cultivated to provide strong and reliable answers to those questions? Experimental..
Colon cancer screening in 2005: status and challengesDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, North Carolina 27599-7080, USA
Gastroenterology 128:1685-95. 2005
Sources of bias in specimens for research about molecular markers for cancerDavid F Ransohoff
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
J Clin Oncol 28:698-704. 2010..An appreciation of the separateness of these two processes-and placing investigators with appropriate expertise in charge of each-may increase the reliability of research about cancer biomarkers...- Rules of evidence for cancer molecular-marker discovery and validationDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, 27599-7080, USA
Nat Rev Cancer 4:309-14. 2004 - Lessons from controversy: ovarian cancer screening and serum proteomicsDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, Bioinformatics Bldg 4103, Chapel Hill, NC 27599 7080, USA
J Natl Cancer Inst 97:315-9. 2005..To address such threats and to realize the potential of new -omics technology will require application of appropriate rules of evidence in the design, conduct, and interpretation of clinical research about molecular markers... - Assessment of serum proteomics to detect large colon adenomasDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
Cancer Epidemiol Biomarkers Prev 17:2188-93. 2008..They also highlight the importance of understanding sources of "noise" and "bias" in studies of proteomics assays... - How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study designDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, 4103 Bioinformatics Building, Chapel Hill, NC 27599 7080, USA
J Clin Epidemiol 60:1205-19. 2007..The objective is to help improve the reliability and efficiency of development of molecular markers for cancer diagnosis... - Bias as a threat to the validity of cancer molecular-marker researchDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
Nat Rev Cancer 5:142-9. 2005.... - What is the role of iFOBT in screening for colorectal cancer?David F Ransohoff
CB7080, University of North Carolina, Chapel Hill, NC 27599 7080, USA
Gut 56:1343-4. 2007 - Proteomics research to discover markers: what can we learn from Netflix?David F Ransohoff
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
Clin Chem 56:172-6. 2010..What is the role of better mathematical or statistical analysis in improving the situation?.. - Cancer. Developing molecular biomarkers for cancerDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7080, USA
Science 299:1679-80. 2003 - Promises and limitations of biomarkersDavid F Ransohoff
University of North Carolina at Chapel Hill, 27599 7360, USA
Recent Results Cancer Res 181:55-9. 2009..This essay discusses chance and bias as threats to validity that can explain the huge disconnect between promise and product, along with approaches to address those threats... - Lessons from the UK sigmoidoscopy screening trialDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Lancet 359:1266-7. 2002 - Screening colonoscopy in balance. Issues of implementationDavid F Ransohoff
Department of Medicine, CB 7080, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
Gastroenterol Clin North Am 31:1031-44, vii. 2002..Noninvasive methods for colon cancer screening may reduce the need for colonoscopy in the future... - Recommendations for post-polypectomy surveillance in community practiceDavid F Ransohoff
Department of Medicine and Epidemiology, CB 7080, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
Dig Dis Sci 56:2623-30. 2011..Decisions about surveillance interval are based in part on polyp size, histology, and number... - Clinical practice. Screening for colorectal cancerDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, 27599-7080, USA
N Engl J Med 346:40-4. 2002 - Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedbackDavid F Ransohoff
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Am J Med 113:663-7. 2002..Interventions should be considered to temper possible overenthusiasm for screening and treatment... - Challenges and opportunities in evaluating diagnostic testsDavid F Ransohoff
University of North Carolina at Chapel Hill, CB 7080 724 Burnett Womack, Chapel Hill, NC 27599 7080, USA
J Clin Epidemiol 55:1178-82. 2002.... - Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk populationThomas F Imperiale
Department of Medicine, Indiana University, and the Regenstrief Institute, Indianapolis, IN 46202, USA
N Engl J Med 351:2704-14. 2004.... - Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific reviewNicholas Shaheen
Division of Digestive Diseases and Nutrition, Center for Esophageal Disease and Swallowing, CB 7080, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7080, USA
JAMA 287:1972-81. 2002..Some have recommended that patients with chronic reflux symptoms undergo upper endoscopy to assess for Barrett esophagus and to screen for cancer... - Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applicationsNicholas Shaheen
Division of Digestive Diseases and Nutrition, Center for Esophageal Disease and Swallowing, CB 7080, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7080, USA
JAMA 287:1982-6. 2002..Applying data reviewed in the companion article, we propose practical answers to common clinical situations regarding care of patients with reflux. We also present an algorithm for treatment of patients with chronic GERD symptoms... - Understanding differences in the guidelines for colorectal cancer screeningThomas F Imperiale
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
Gastroenterology 138:1642-1647.e1. 2010..In this issue of Gastroenterology, the editors present 2 expert perspectives on the colorectal screening guidelines published in the May 2008 issue of the journal... - Interpretations of 'appropriate' minority inclusion in clinical researchGiselle Corbie-Smith
Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Am J Med 116:249-52. 2004..To expand scientific knowledge about the health of minority populations, investigators should be expected to state which goal they have selected and why that goal is appropriate as compared with other possible goals... - Adequacy of reporting race/ethnicity in clinical trials in areas of health disparitiesGiselle Corbie-Smith
Department of Social Medicine, University of North Carolina at Chapel Hill, CB 7240, Chapel Hill, NC 27599, USA
J Clin Epidemiol 56:416-20. 2003..Although federal initiatives mandate inclusion of minority groups in research, that inclusion has not translated to reporting of results that might guide therapeutic decisions... - Five-year risk of colorectal neoplasia after negative screening colonoscopyThomas F Imperiale
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
N Engl J Med 359:1218-24. 2008..The appropriate interval for endoscopic rescreening after a negative colonoscopic examination is uncertain... - Variation in polyp detection rates at screening colonoscopyThomas F Imperiale
Division of Gastroenterology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
Gastrointest Endosc 69:1288-95. 2009..Variation in polyp detection among endoscopists has been used to justify the need for establishing quality standards for colonoscopy performance... - International variation in screening mammography interpretations in community-based programsJoann G Elmore
Department of Medicine, University of Washington, Seattle, USA
J Natl Cancer Inst 95:1384-93. 2003..To evaluate international variability in mammography interpretation, we analyzed published reports from community-based screening programs from around the world... - Achieving quality in flexible sigmoidoscopy screening for colorectal cancerO S Ashley
School of Public Health, University of North Carolina at Chapel Hill, USA
Am J Med 111:643-53. 2001..This review describes elements that characterize high-quality examinations and identifies resources for in-depth information on performing flexible sigmoidoscopy... - CON: Immediate colonoscopy is not necessary in patients who have polyps smaller than 1 cm on computed tomographic colonographyDavid F Ransohoff
Department of Medicine, University of North Carolina, Chapel Hill, USA
Am J Gastroenterol 100:1905-7; discussion 1907-8. 2005 - Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomyPauline A Mysliwiec
National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Ann Intern Med 141:264-71. 2004..Guidelines recommend surveillance after polypectomy at 3 to 5 years for a small adenoma, and follow-up is not advised for hyperplastic polyps. The intensity of physicians' surveillance is largely unstudied... - Implications of new colorectal cancer screening technologies for primary care practiceAnn G Zauber
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA
Med Care 46:S138-46. 2008 - Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancerThomas F Imperiale
Indiana University School of Medicine, Indiana University, Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA
Ann Intern Med 139:959-65. 2003..If it is validated in other cohorts or groups, the index could be used to tailor endoscopic screening for colorectal cancer... - Virtual colonoscopy--what it can do vs what it will doDavid F Ransohoff
JAMA 291:1772-4. 2004 - Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry tradeIsaac M Lipkus
Duke University Medical Center, Durham, NC 27701, USA
Prev Med 37:513-9. 2003.... - Fecal DNA tests for colorectal cancerDavid F Ransohoff
N Engl J Med 346:1912-3; author reply 1912-3. 2002 - Results of screening colonoscopy among persons 40 to 49 years of ageThomas F Imperiale
Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, USA
N Engl J Med 346:1781-5. 2002..The low yield of screening colonoscopy in this age group is consistent with current recommendations about the age at which to begin screening in persons at average risk... - Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for serviceAnna P Schenck
The Carolinas Center for Medical Excellence, Cary, NC 27511 8598, USA
Cancer Epidemiol Biomarkers Prev 17:799-804. 2008..Medicare claims have been used to measure CRC testing but the validity of using claims to measure fecal occult blood tests (FOBT) has not been established... - Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasiaRobert H Fletcher
Cancer 109:1925-6; author reply 1926. 2007 - A national survey of primary care physicians' methods for screening for fecal occult bloodMarion R Nadel
Centers for Disease Control and Prevention and American Cancer Society, Atlanta, Georgia 30341 3717, ISA
Ann Intern Med 142:86-94. 2005..Although the test is simple, implementation requires adherence to specific techniques of testing and follow-up of abnormal results... - Data sources for measuring colorectal endoscopy use among Medicare enrolleesAnna P Schenck
The Carolinas Center for Medical Excellence, 100 Regency Forest, Suite 200, Cary, NC 27511 8598, USA
Cancer Epidemiol Biomarkers Prev 16:2118-27. 2007..We compared ascertainment of sigmoidoscopy and colonoscopy between three data sources: self reports, Medicare claims, and medical records... - Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristicsJames E Allison
Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612 2304, USA
J Natl Cancer Inst 99:1462-70. 2007..Thus, improving the sensitivity of FOBT should make colon cancer screening programs that use these tests more effective... - Have we oversold colonoscopy?David F Ransohoff
Gastroenterology 129:1815. 2005 - Reader response to colonoscopy versus sigmoidoscopySteven M Woolf
Fam Med 38:311-2; author reply 312-3. 2006 - Gene-expression signatures in breast cancerDavid F Ransohoff
N Engl J Med 348:1715-7; author reply 1715-7. 2003 - Discovery-based research and fishingDavid F Ransohoff
Gastroenterology 125:290. 2003 - Predicting risk for the appearance of melanomaFrank L Meyskens
J Clin Oncol 24:3522-3. 2006 - Evaluating discovery-based research: when biologic reasoning cannot workDavid F Ransohoff
Gastroenterology 127:1028. 2004 - The process to discover and develop biomarkers for cancer: a work in progressDavid F Ransohoff
J Natl Cancer Inst 100:1419-20. 2008 - Improving colorectal cancer screening in primary care practice: innovative strategies and future directionsCarrie N Klabunde
Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
J Gen Intern Med 22:1195-205. 2007..Active engagement and support of practices are essential for the enormous potential of CRC screening to be realized... - Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) studyH Gilbert Welch
VA Outcomes Group, White River Junction VA Medical Center, 215 N Main St, VA Outcomes Group, 11B, White River Junction, VT 05009, USA
Arch Intern Med 167:2289-95. 2007....
Research Grants
- CLINICAL RESEARCH CURRICULUMDavid Ransohoff; Fiscal Year: 2004..abstract_text> ..
- Colonoscopy Utilization in North CarolinaDavid Ransohoff; Fiscal Year: 2006..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..